SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SARS and Avian Flu
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Elroy Jetson who wrote (2718)10/15/2005 1:48:17 PM
From: scaram(o)uche  Read Replies (2) of 4232
 
>> Not one viral IGG product that I'm aware of has ever led to an approved drug, in spite of decades of trials. <<

Purely an economic issue...... getting titers high enough from volunteers selected among random donors, and the expense of providing an intravenous product. The antibodies are there, and they've been shown to provide potent anti-viral protection in a variety of studies.

>> You were misinformed when someone told you that monoclonal antibodies are not used to treat sepsis. <<

I didn't say that one can't find model systems and trials where MAbs have been effective. I said that you were wrong when you said that........

>> SEPSIS is now treated with man-made monoclonal antibodies to the antigen the immune system is responding to. <<

And I'm correct. Yes, you can provide GREAT protection with serotype-specific MAbs to a variety of Gram-negatives. One can't, however, make a cocktail that has any economic viability as a product.

You are flat out wrong. TNF is not "the antigen the immune system is responding to", and E5 and HA-1A failed miserably, together with every other MAb that was purportedly specific for core endotoxin, in advanced testing. Miserably. A few links to crap preliminary studies from 1991 won't buy you much.

A little basckground reading for you, Mr. Jetson.....

pubmedcentral.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News